Genfit: publication of the 2024 extra-financial performance report (fiscal year 2023)

Lille (france), cambridge (massachusetts, usa), zurich (switzerland), april 25, 2024 - genfit (nasdaq and euronext: gnft), a late-stage biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases, today announced the publication of its 2024 extra-financial performance report (fiscal year 2023).
GNFT Ratings Summary
GNFT Quant Ranking